Nanobiotix SA

NBTX · NYSE

$29.36+$0.17 (+0.58%)TodayMarket closed · Oct 23, 4:44 PM ET

Prev close $29.19

NBTX analyst rating

BuyConsensus of 4 analysts over the last 12 months. 75% rate it a buy.

Strong buy0
Buy3
Hold1
Underperform0
Sell0

12-month price target · 8 analysts

Average $56.39 (+92.1% upside)

Low: $43.37
Now: $29.36
High: $67.63

Upgrades and downgrades

The latest rating actions, newest first

NBTX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Guggenheim	Sep 15, 2026	Initiates	Buy	$64.00	31%
Leerink Partners	Jun 4, 2026	Maintains	Outperform	$37.00 → $46.00	31%
UBS	May 1, 2026	Maintains	Neutral	$3.50 → $30.00	41%
Guggenheim	Apr 2, 2026	Maintains	Buy	$26.00 → $36.00	62%
Guggenheim	Feb 6, 2026	Maintains	Buy	$8.00 → $26.00	62%

The case for and against

Updated Oct 17, 2026

Bull case

Nanobiotix is viewed favorably because its first-in-class, physics-based radioenhancer NBTXR3 has already shown clinical proof-of-concept in Phase 1/2 studies and is now advancing through pivotal testing in large, high-unmet-need solid-tumor settings. The JNJ partnership meaningfully de-risks development by providing external validation, global commercialization capability, and an economics model tied to milestones and royalties, while the company’s broad applicability in radiotherapy could fit seamlessly into existing practice. Financially, the company ended 1Q26 with €42.1M in cash and equivalents, with runway into 2029, and the cited addressable markets are substantial, including a $1.5Bn TAM in chemo-ineligible LA-HNSCC and $5.5Bn in Stage III NSCLC.

Bear case

Nanobiotix is exposed to substantial fundamental risk because its valuation depends on unproven clinical, regulatory, and commercial execution across a highly novel lead program, where trial failure, safety concerns, or approval setbacks could quickly impair the thesis. The company also faces execution and financial strain from meaningful debt, possible additional financing needs before cash flow turns positive, and the risk that R&D, commercialization, and pipeline spending exceed estimates. Further downside comes from undisclosed collaboration milestones, potential dilution, and the chance that product launches, sales, MedTech performance, or legal and pricing developments fall short of expectations.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.